Annexin a2 is implicated in multi-drug-resistance in gastric cancer through p38mapk and AKT pathway

Neoplasma

Volumn 61, Issue 6, 2014, Pages 627-637

  Zhang, Z D ^a   Li, Y ^a   Fan, L Q ^a   Zhao, Q ^a   Tan, B B ^a   Zhao, X F ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Annexin A2; Gastric cancer; Multidrug resistance; SGC7901 DDP cells; siRNA

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL) IMIDAZOLE; CISPLATIN; DOXORUBICIN; FLUOROURACIL; LIPOCORTIN 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SMALL INTERFERING RNA; SULFORHODAMINE B; TRICIRIBINE; UNCLASSIFIED DRUG; ANXA2 PROTEIN, HUMAN;

ARTICLE; CELL CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RNA EXTRACTION; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR DIFFERENTIATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; GENETICS; PATHOLOGY; PHYSIOLOGY; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANNEXIN A2; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84910605334     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2014_078     Document Type: Article

References (38)

1. JEMAL A, BRAY F, Center MM, FERLAY J, WARD E et al: Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90. http://dx.doi.org/10.3322/caac.20107
2. MCCRACKEN M, OLSEN M, CHEN MS JR, JEMAL A, THUN M et al: Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin 2007; 57: 190-205. http://dx.doi.org/10.3322/canjclin.57.4.190
3. ZHAO P, DAI M, CHEN W, LI N: Cancer trends in China. Jpn J Clin Oncol 2010; 40: 281-285. http://dx.doi.org/10.1093/jjco/hyp187
4. QIU MZ, WANG ZQ, LUO HY, ZHANG DS, ZHOU ZW et al: Prognostic analysis in node-negative gastric cancer patients in China. Tumour Biol 2011; 32: 489-492. http://dx.doi.org/10.1007/s13277-010-0142-5
5. NISHIYAMA M: Chemotherapy for gastric cancer in Japan. Int J Clin Oncol 2008; 13: 191-192. http://dx.doi.org/10.1007/s10147-008-0790-2
6. CUNNINGHAM D, ALLUM WH, STENNING SP, THOMPSON JN, VAN DE VELDE CJ et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20. http://dx.doi.org/10.1056/NEJMoa055531
7. CERVANTES A, RODA D, TARAZONA N, ROSELLO S, Perez-Fidalgo JA: Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev 2013; 39: 60-67. http://dx.doi.org/10.1016/j.ctrv.2012.09.007
8. BROXTERMAN HJ, GOTINK KJ, VERHEUL HM: Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat 2009; 12: 114-126. http://dx.doi.org/10.1016/j.drup.2009.07.001
9. MAI J, WAISMAN DM, SLOANE BF: Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. Biochim Biophys Acta 2000; 1477: 215-230. http://dx.doi.org/10.1016/S0167-4838(99)00274-5
10. OLIFERENKO S, PAIHA K, HARDER T, GERKE V, SCHWARZLER C et al: Analysis of CD44-containing lipid rafts: Recruitment of annexin II and stabilization by the actin cytoskeleton. J Cell Biol 1999; 146: 843-854. http://dx.doi.org/10.1083/jcb.146.4.843
11. SURETTE AP, MADUREIRA PA, PHIPPS KD, MILLER VA, SVENNINGSSON P et al: Regulation of fibrinolysis by S100A10 in vivo. Blood 2011; 118: 3172-3181. http://dx.doi.org/10.1182/blood-2011-05-353482
12. ZHAO P, ZHANG W, WANG SJ, YU XL, TANG J et al: HAb18G/CD147 promotes cell motility by regulating annexin II-activated RhoA and Rac1 signaling pathways in hepatocellular carcinoma cells. Hepatology 2011; 54: 2012-2024. http://dx.doi.org/10.1002/hep.24592
13. WOODHAM AW, DA SILVA DM, SKEATE JG, RAFF AB, AMBROSO MR et al: The S100A10 subunit of the ANXA2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS One 2012; 7: e43519. http://dx.doi.org/10.1371/journal.pone.0043519
14. MARTIN M, LEFFLER J, BLOM AM: ANXA2 and A5 serve as new ligands for C1q on apoptotic cells. J Biol Chem 2012; 287: 33733-33744. http://dx.doi.org/10.1074/jbc.M112.341339
15. MADUREIRA PA, HILL R, MILLER VA, GIACOMANTONIO C, LEE PW et al: ANXA2 is a novel cellular redox regulatory protein involved in tumorigenesis 2011, 2: 1075-1093.
16. SUN Y, GAO G, CAI J, WANG Y, QU X et al: ANXA2 is a discriminative serological candidate in early hepatocellular carcinoma. Carcinogenesis 2013; 34: 595-604. http://dx.doi.org/10.1093/carcin/bgs372
17. YANG T, PENG H, WANG J, YANG J, NICE EC et al: Prognostic and diagnostic significance of ANXA2 in colorectal cancer. Colorectal Dis 2013; 15: e373-381. http://dx.doi.org/10.1111/codi.12207
18. DENG S, JING B, XING T, HOU L, YANG Z: Overexpression of ANXA2 is associated with abnormal ubiquitination in breast cancer. Genomics Proteomics Bioinformatics 2012; 10: 153-157. http://dx.doi.org/10.1016/j.gpb.2011.12.001
19. LOKMAN NA, ELDER AS, WEEN MP, PYRAGIUS CE, HOFFMANN P et al: ANXA2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis. Oncotarget 2013; 4: 1199-1211.
20. ZHANG Q, YE Z, YANG Q, HE X, WANG H et al: Upregulated expression of annexin II is a prognostic marker for patients with gastric cancer. World J Surg Oncol 2012; 10: 103. http://dx.doi.org/10.1186/1477-7819-10-103
21. LI W, LI L, LIU Z, LIU C, LIU Z et al: Expression of the full-length telomerase reverse transcriptase (hTERT) transcript in both malignant and normal gastric tissues. Cancer Lett 2008; 260: 28-36. http://dx.doi.org/10.1016/j.canlet.2007.10.018
22. LIU JW, SHEN JJ, Tanzillo-Swarts A, BHATIA B, MALDONADO CM et al: Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene 2003; 22: 1475-1485. http://dx.doi.org/10.1038/sj.onc.1206196
23. QI YJ, HE QY, MA YF, DU YW, LIU GC et al: Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma. J Cell Biochem 2008; 104: 1625-1635. http://dx.doi.org/10.1002/jcb.21727
24. Pena-Alonso E, RODRIGO JP, PARRA IC, PEDRERO JM, MEANA MV et al: ANXA2 localizes to the basal epithelial layer and is down-regulated in dysplasia and head and neck squamous cell carcinoma. Cancer Lett 2008; 263: 89-98. http://dx.doi.org/10.1016/j.canlet.2007.12.029
25. ZHANG Q, YE Z, YANG Q, HE X, WANG H et al: Upregulated expression of annexin II is a prognostic marker for patients with gastric cancer. World J Surg Oncol 2012; 10: 103. http://dx.doi.org/10.1186/1477-7819-10-103
26. EMOTO K, SAWADA H, YAMADA Y, FUJIMOTO H, Taka-Hama Y et al: Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res 2001; 21: 1339-1345.
27. LI Y, TAN BB, ZHAO Q, FAN LQ, LIU Y et al: Tumor chemosensitivity is correlated with expression of multidrug resistance associated factors in variously differentiated gastric carcinoma tissues. Hepatogastroenterology 2013; 60: 213-216.
28. ZHANG F, ZHANG L, ZHANG B, WEI X, YANG Y et al: Anxa2 plays a critical role in enhanced invasiveness of the multidrug resistant human breast cancer cells. J Proteome Res 2009; 8: 5041-5047. http://dx.doi.org/10.1021/pr900461c
29. MENG Q, LEI T, ZHANG M, ZHAO J, ZHAO XH et al: Identification of proteins differentially expressed in adriamycin-resistant (pumc-91/ADM) and parental (pumc-91) human bladder cancer cell lines by proteome analysis. J Cancer Res Clin Oncol 2013; 139: 509-519. http://dx.doi.org/10.1007/s00432-012-1350-8
30. PIACENTINI P, DURANTE E, TROLESE A, MERCANTI A, BONETTI A: Weekly Taxotere and cisplatin with continuousinfusion 5-fluoruracil for the treatment of advanced gastric and esophageal cancer: a prospective, observational, singleinstitution experience. Gastric Cancer 2012; 15: 106-110. http://dx.doi.org/10.1007/s10120-011-0078-5
31. HANNON GJ: RNA interference. Nature 2002; 418: 244-251. http://dx.doi.org/10.1038/418244a
32. LUCIO KA, ROCHA GDA G, Moncao-Ribeiro LC, FERNANDES J, TAKIYA CM et al: Oleanolic acid initiates apoptosis in non-small cell lung cancer cell lines and reduces metastasis of a B16F10 melanoma model in vivo. PLoS One 2011; 6: e28596. http://dx.doi.org/10.1371/journal.pone.0028596
33. SHA ROM F J: A B C M U LT I DRU G T R A N SP ORTERS: structure, function and role in chemoresistance. Pharmacogenomics 2008; 9: 105-127. http://dx.doi.org/10.2217/14622416.9.1.105
34. WANG Y, LIU L, LIU X, ZHANG H, LIU J et al: Shugoshin1 enhances multidrug resistance of gastric cancer cells by regulating MRP1, Bcl-2, and Bax genes. Tumour Biol 2013; 34: 2205-2214. http://dx.doi.org/10.1007/s13277-013-0758-3
35. LIANG J, GE F, GUO C, LUO G, WANG X et al: Inhibition of PI3K/Akt partially leads to the inhibition of PrP(C) induced drug resistance in gastric cancer cells. FEBS J 2009; 276: 685-694. http://dx.doi.org/10.1111/j.1742-4658.2008.06816.x
36. TAKEUCHI A, ETO M, SHIOTA M, TATSUGAMI K, YOKOMIZO A et al: Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation. Int J Oncol 2012; 40: 1691-1696.
37. GUO X, MA N, WANG J, SONG J, BU X et al: Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer 2008; 8: 375. http://dx.doi.org/10.1186/1471-2407-8-375
38. ZHU MM, TONG JL, XU Q, NIE F, XU XT et al: Increased JNK1 signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer. PLoS One. 2012, 7(8): e41763. http://dx.doi.org/10.1371/journal.pone.0041763